1. Home
  2. NLSP vs TBI Comparison

NLSP vs TBI Comparison

Compare NLSP & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • TBI
  • Stock Information
  • Founded
  • NLSP 2015
  • TBI 1985
  • Country
  • NLSP Switzerland
  • TBI United States
  • Employees
  • NLSP N/A
  • TBI N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • TBI Professional Services
  • Sector
  • NLSP Health Care
  • TBI Consumer Discretionary
  • Exchange
  • NLSP Nasdaq
  • TBI Nasdaq
  • Market Cap
  • NLSP 12.4M
  • TBI 204.9M
  • IPO Year
  • NLSP 2021
  • TBI 1996
  • Fundamental
  • Price
  • NLSP $2.13
  • TBI $6.15
  • Analyst Decision
  • NLSP
  • TBI Buy
  • Analyst Count
  • NLSP 0
  • TBI 1
  • Target Price
  • NLSP N/A
  • TBI $10.00
  • AVG Volume (30 Days)
  • NLSP 268.4K
  • TBI 195.4K
  • Earning Date
  • NLSP 07-22-2025
  • TBI 08-04-2025
  • Dividend Yield
  • NLSP N/A
  • TBI N/A
  • EPS Growth
  • NLSP N/A
  • TBI N/A
  • EPS
  • NLSP N/A
  • TBI N/A
  • Revenue
  • NLSP N/A
  • TBI $1,534,794,000.00
  • Revenue This Year
  • NLSP N/A
  • TBI $0.80
  • Revenue Next Year
  • NLSP N/A
  • TBI $6.90
  • P/E Ratio
  • NLSP N/A
  • TBI N/A
  • Revenue Growth
  • NLSP N/A
  • TBI N/A
  • 52 Week Low
  • NLSP $1.30
  • TBI $3.45
  • 52 Week High
  • NLSP $15.59
  • TBI $12.29
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 43.58
  • TBI 45.21
  • Support Level
  • NLSP $2.20
  • TBI $6.06
  • Resistance Level
  • NLSP $2.33
  • TBI $6.89
  • Average True Range (ATR)
  • NLSP 0.25
  • TBI 0.26
  • MACD
  • NLSP -0.07
  • TBI -0.10
  • Stochastic Oscillator
  • NLSP 6.86
  • TBI 14.65

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.

Share on Social Networks: